Stocktoria
AMARIN CORP PLCUK AMRN
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1993-04-01
AMARIN CORP PLCUK financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $213.6M | $228.6M | $306.9M | $369.2M | $583.2M | $614.1M | $429.8M | $229.2M | $181.1M | $130.1M |
| Gross profit | $120.9M | $81.4M | $165.5M | $242.5M | $461.9M | $482.6M | $333.7M | $174.7M | $136.2M | $95.7M |
| R&D expense | $19.8M | $20.9M | $22.2M | $30.4M | $29.3M | $39.0M | $34.4M | $55.9M | $47.2M | $50.0M |
| SG&A expense | $115.0M | $152.3M | $199.9M | $304.4M | $408.3M | $463.3M | $323.6M | $227.0M | $134.5M | $111.4M |
| Operating income | -$50.2M | -$91.8M | -$67.6M | -$105.9M | $10.5M | -$19.7M | -$24.3M | -$108.2M | -$45.6M | -$65.6M |
| Interest expense | $7,000 | $7,000 | $8,000 | $15,000 | $129,000 | $2.6M | $6.6M | $8.9M | $9.8M | $18.7M |
| Income tax | $2.8M | $5.0M | $5.4M | $2.0M | $3.6M | $745,000 | $164,000 | $96,000 | $13.0M | $10.0M |
| Net income | -$38.8M | -$82.2M | -$59.1M | -$105.8M | $7.7M | -$18.0M | -$22.6M | -$116.4M | -$67.9M | -$86.3M |
| EPS (diluted) | $-0.09 | $-0.20 | $-0.15 | $-0.26 | $0.02 | $-0.05 | $-0.07 | $-0.39 | $-0.25 | $-0.41 |
| Operating cash flow | $6.7M | -$31.0M | $6.9M | -$180.1M | -$66.5M | -$21.7M | -$9.4M | -$94.7M | -$32.8M | -$71.8M |
| Free cash flow | — | — | — | — | — | -$22.0M | -$11.8M | -$94.8M | -$32.8M | -$71.8M |
| Cash & equivalents | $134.7M | $121.0M | $199.3M | $217.7M | $219.5M | $187.0M | $644.6M | $249.2M | $73.6M | $98.3M |
| Inventory | $195.9M | $166.0M | $258.6M | $228.7M | $234.7M | $188.9M | $76.8M | $57.8M | $30.3M | $20.5M |
| Total assets | $670.8M | $685.3M | $831.7M | $886.2M | $1.1B | $966.0M | $882.2M | $385.7M | $161.6M | $167.0M |
| Total liabilities | $211.5M | $199.2M | $279.6M | $290.8M | $401.0M | $338.5M | $273.9M | $233.4M | $226.7M | $176.1M |
| Shareholders' equity | $459.3M | $486.2M | $552.1M | $595.3M | $667.1M | $627.5M | $608.3M | $152.3M | -$65.1M | -$9.1M |
Growth · year-over-year · Revenue CAGR 5.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -6.5% | -25.5% | -16.9% | -36.7% | -5.0% | +42.9% | +87.5% | +26.6% | +39.2% | +59.1% |
| Net income growth | — | — | — | -1468.9% | — | — | — | — | — | — |
| EPS growth | — | — | — | -1400.0% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.